Eric M. Carrino


Eric M. Carrino represents individual and institutional shareholders, businesses, and consumers in complex litigation in state and federal courts across the country. Mr. Carrino has litigated cases involving unfair mergers, related-party transactions, accounting fraud, insider trading, false and misleading statements, and other types of fiduciary and corporate misconduct at public and private companies. For his work, Mr. Carrino has been recognized by his peers as a Super Lawyers Rising Star for six consecutive years.

Mr. Carrino holds a Juris Doctor from the University of San Diego School of Law with a concentration in corporate and securities law. He graduated with honors and was the recipient of the Law Faculty Honor Scholarship and the Faculty Outstanding Scholar Award. While in law school, he was a member of the San Diego Law Review and clerked for a Los Angeles-based aviation and aerospace law firm, as well as for Robbins LLP. Mr. Carrino graduated with honors from the University of California, Los Angeles with a Bachelor of Science degree in Political Science.


  • University of San Diego School of Law (J.D. 2015)
  • University of California, Los Angeles (B.A. 2010)



  • California
  • U.S. District Court for the Northern and Southern District of California
  • U.S. District Court for the Eastern District of Wisconsin



  • Super Lawyers Rising Star (2018-2023)



  • Association of Business Trial Lawyers
  • Public Justice Foundation
  • Hon. William B. Enright American Inn of Court (2018-2020)


Mr. Carrino was part of the team that represented plaintiffs in a shareholder derivative matter on behalf of Amneal Pharmaceuticals, Inc. The complaint alleged that Amneal’s controlling stockholders duped the Company into purchasing their affiliate’s high-risk, early-stage development drugs for $100 million, plus potentially millions more in “milestone” and royalty payments through a conflicted sales process. As a result of the deal, Amneal would then have to spend tens of millions of dollars to develop the drugs, which had no guarantee of success, while the defendants unjustly reaped the benefits. Mr. Carrino leveraged his corporate valuation experience to help negotiate a settlement agreement that included a $11.5 million reduction in royalty payments payable by Amneal and significant changes to and oversight of Amneal’s Conflicts Committee and policies regarding related party transactions. Thiele v. Kashiv Biosciences, LLC, et al., No. 2022-0272-LWW (Del. Ch. July 26, 2023).


Mr. Carrino represented the plaintiffs in the Nevada state court derivative action who alleged that defendants made false and misleading statements regarding Workhorse’s future business prospects, including its ability to win all, or a significant portion of, the United States Postal Service’s multibillion dollar contract to replace its aging fleet of vehicles with electric vehicles, and sales of stock by Workhorse directors and officers while the Company’s stock price was allegedly inflated by those false and misleading statements. After extensive negotiations that included the parties to various derivative cases involving Workhorse, counsel reached a settlement that included $12.5 million to the Company, the creation of a Disclosure Controls Committee and Chief Compliance Officer Position, and numerous other substantial reforms designed to prevent similar future wrongdoing. In Re Workhorse Group Inc. Stockholder Derivative Litigation, No. A-21-833050-B (NV. Dist. Ct. -Clark Cnty).

Skip to content